No Effect of One-Year Treatment with Indomethacin on Alzheimer's Disease Progression: A Randomized Controlled Trial
2008

Indomethacin and Alzheimer's Disease Progression

Sample size: 51 publication Evidence: low

Author Information

Author(s): de Jong Daniëlle, Jansen René, Hoefnagels Willibrord, Jellesma-Eggenkamp Marja, Verbeek Marcel, Borm George, Kremer Berry

Primary Institution: Radboud University Nijmegen Medical Center

Hypothesis

Indomethacin may retard the clinical progression of Alzheimer's disease.

Conclusion

The study found that indomethacin did not significantly slow the progression of Alzheimer's disease.

Supporting Evidence

  • The deterioration on the ADAS-cog was less in the indomethacin group than in the placebo group.
  • The study was discontinued prematurely due to recruitment difficulties.
  • No significant differences were found in secondary outcome measures.

Takeaway

The study tested if a medicine called indomethacin could help people with Alzheimer's disease, but it didn't work as hoped.

Methodology

This was a double-blind, randomized, placebo-controlled trial with 51 patients receiving either indomethacin or placebo for one year.

Potential Biases

The study population was highly selected, which may not represent the average Alzheimer's disease population.

Limitations

The study was underpowered due to recruitment difficulties and had strict exclusion criteria, limiting generalizability.

Participant Demographics

Patients had mild to moderate Alzheimer's disease, with a mean age of approximately 72 years.

Statistical Information

Confidence Interval

−4.5–7.5

Digital Object Identifier (DOI)

10.1371/journal.pone.0001475

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication